Abstract 3854
Background
The aim of this study is to determine the palliative care needs of cancer patients and to examine the knowledge and expectations of the patients and their families about palliative care.
Methods
The research was conducted as a descriptive study.The sampling has formed 110 patients and 110 patients families who received a treatment between the dates of June- August 2017. The datas were collected for using socio-demographic and palliative care survey and questionnaire form, Palliative Performance Scale and Edmonton Symptom Scale.
Results
80.9% of the patients have received information about the disease. 76.4% of the patients and 60% their families weren’t aware of palliative/supportive care, and 49.1% of the patient/55.5% of the family have been seen worries and expectations for treatment and care. These anxieties of in the patients 46.4% can’t be like former ones and 31.8% have got a pain, while the anxieties of in the patients families 43.6% were losing their patients life and 33.6% is the extension of the treatments period. 63.6% of the families had problems with maintaining their daily work. 25% of the patients defined palliative care as end-of-life care, while others patients defined it as a symptom management and supportive treatment. Expectations of 99.1% the patients and 97.3% of their families were to learn the treatment and care plan; 97.3% of the patients and 80% of the families were to be included and supported in the decisions taken; 97.3% of patients and 97.3 of the families were to be informed about cost of treatment-care; in the treatment process 77.3% of the patients / 85.5% of the families were wants to be supported psychological and, 77.3% of the patients / 50% of the families were want to be supported with receive religious and; 84.5% of the patients / 70% of the families were want to be told the diagnosis.
Conclusions
it has been suggested that patients and their families should be informed about the palliative care, physical, psychosocial, support from the spirütüel direction, while it is proposed to development of tools for determination of their needs and requirements. Key words: Palliative care, Supportive treatment, Cancer, Knowledge and expectation, Patient and patient family.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Özlem Topkaya.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract